NCT04344782: CORIMMUNO-BEVA

Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin®/Zeribev®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort

Status unknown Phase 2 Last updated 17 April 2020

What this trial tests

Phase 2 trial testing Bevacizumab Injection in COVID19 Pneumonia in 130 participants. Status unknown.

Timeline

15 April 2020

Primary endpoint
30 September 2020

30 November 2020

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	130
Start date	15 April 2020
Primary completion	30 September 2020
Estimated completion	30 November 2020

Drugs / interventions tested

• Bevacizumab Injection — full drug profile →

Conditions studied

• COVID19 Pneumonia — all drugs for COVID19 Pneumonia →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

18 and older, any sex, with COVID19 Pneumonia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Bevacizumab, ZERIBEV® (Pfizer)/AVASTIN® (Roche) 25 mg/ml ®, is a recombinant humanised monoclonal IgG1 antibody It seems interesting to use bevacizumab in severe patients infected with SARS-CoV-2 requiring hospitalization in conventional unit or in ICU.

This protocol CORIMUNO19-BEVA will evaluate the efficacy and safety of AVASTIN®/ ZERIBEV® (bevacizumab) COVID-19 patients hospitalized in conventional units.

This phase 2 randomized clinical trial aimed at evaluating the efficacy and safety of AVASTIN®/ ZERIBEV® (bevacizumab) alone versus standard of care (SoC) in patients hospitalized in conventional units.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. COVID-19: the vasculature unleashed.
   Teuwen LA, Geldhof V, Pasut A, Carmeliet P. · · 2020 · cited 805× · PMID 32439870 · DOI 10.1038/s41577-020-0343-0
2. Neutrophil Extracellular Traps (NETs) and Damage-Associated Molecular Patterns (DAMPs): Two Potential Targets for COVID-19 Treatment.
   Cicco S, Cicco G, Racanelli V, Vacca A. · · 2020 · cited 142× · PMID 32724296 · DOI 10.1155/2020/7527953
3. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
   Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, et al · · 2021 · cited 126× · PMID 34473343 · DOI 10.1002/14651858.cd013825.pub2
4. Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives.
   Sarkar C, Mondal M, Torequl Islam M, Martorell M, et al · · 2020 · cited 64× · PMID 33041814 · DOI 10.3389/fphar.2020.572870
5. Repurposing anticancer drugs for the management of COVID-19.
   El Bairi K, Trapani D, Petrillo A, Le Page C, et al · · 2020 · cited 59× · PMID 33125946 · DOI 10.1016/j.ejca.2020.09.014
6. Immunobiology and immunotherapy of COVID-19: A clinically updated overview.
   Esmaeilzadeh A, Elahi R. · · 2021 · cited 59× · PMID 33022076 · DOI 10.1002/jcp.30076
7. Vasculopathy and Coagulopathy Associated with SARS-CoV-2 Infection.
   Labò N, Ohnuki H, Tosato G. · · 2020 · cited 57× · PMID 32629875 · DOI 10.3390/cells9071583
8. Inflammatory pathways in COVID-19: Mechanism and therapeutic interventions.
   Jiang Y, Zhao T, Zhou X, Xiang Y, et al · · 2022 · cited 44× · PMID 35923762 · DOI 10.1002/mco2.154